# Inherent Biosciences

**Type:** venture
**Status:** Draft
**Confidence:** Medium
**Focus:** epigenetic diagnostics, male fertility, sperm function, reproductive health, AI biomarkers
**Stage:** Private; Series A; NIH grant-funded
**Location:** Lehi area, UT
**Updated:** 2026-06-19
**Needs-reviewed:** 2026-06-19
**Pull:** *Epigenetic sperm-function testing beyond count and motility — early, but a different diagnostic signal.*
**Relates:** cites [Official Website: Inherent Biosciences](inherent-biosciences-official-website.md)

## Summary

Inherent Biosciences is a Utah-based diagnostics company using epigenetic patterns — gene-expression state rather than genetic variants alone — to assess whether cells are functioning correctly. Its first commercial product is **SpermQT**, marketed through the **Path Fertility** division, an epigenetic sperm-function test intended to improve male-factor fertility diagnosis when standard semen analysis finds nothing wrong.

The platform ambition extends to embryo quality, azoospermia, reproductive cancers, and broader epigenetic medicine, but fertility is the near-term wedge. NIH and NSF grant funding suggests scientific credibility; Series A scale and clinical generalization remain early.

## Impact

Roughly half of infertile couples receive no male-factor explanation from count-and-motility testing even when sperm function is impaired. If epigenetic sperm-function assays improve diagnostic yield and treatment planning, they could shorten time-to-pregnancy and reduce unnecessary procedures — a meaningful but niche clinical impact.

Broader epigenetic-diagnostic impact is speculative: the science is plausible, but epigenetics-based tools have a mixed translation history and require rigorous population validation.

## What They Are Building

Inherent uses AI to identify epigenetic patterns in sperm correlated with fertility outcomes. Path Fertility markets SpermQT to clinicians and couples as a higher-signal alternative to traditional semen analysis. The official website frames additional focus areas — sperm age, embryo quality, azoospermia, reproductive cancers — as future or parallel applications.

## What They Need Now

Likely needs include epigenomics scientists, bioinformaticians, clinical-laboratory operators, reproductive endocrinology KOLs, and reimbursement strategists. Small-team contributors can have high leverage; regulatory and CLIA/LDT pathways for diagnostic products are core constraints.

## Who Could Help

Useful helpers include fertility-clinic distribution partners, NIH grant administrators, reproductive-health payers and reimbursement advisors, and Utah life-sciences ecosystem connectors (Nucleus Utah and related networks).

## Utah Context

Inherent is headquartered in the Lehi area on the Wasatch Front, part of Utah's growing diagnostics and digital-health cluster alongside companies like [Techcyte](techcyte.md) and [Owlet Baby Care](owlet-baby-care.md).

## Evidence

- [Official Website: Inherent Biosciences](inherent-biosciences-official-website.md)
- [Nucleus Utah: Redefining male fertility](https://www.nucleusutah.org/newsroom/redefining-male-fertility-inside-inherent-biosciences-growth)

## Open Questions

- What are SpermQT's validated sensitivity, specificity, and clinical outcomes versus standard semen analysis?
- Reimbursement and payer coverage status for epigenetic fertility testing?
- Can the epigenetic platform generalize beyond fertility to autoimmune, developmental, or aging indications — and on what timeline?
- Epigenetic diagnostics are noisy; what controls reproducibility across labs and populations?